NSE ScannerComparison · NSE · data 2026-11-01
Aurobindo Pharma Ltd vs Cipla Ltd
In plain words
Size: Cipla Ltd is about 1.2 times the market value of Aurobindo Pharma Ltd.
Valuation (P/E): Cipla Ltd 38.5 vs Aurobindo Pharma Ltd 26.3.
Return on equity: Cipla Ltd 11.8% vs Aurobindo Pharma Ltd 9.9%.
Profit growth over 3 years: Aurobindo Pharma Ltd 22.1% a year vs Cipla Ltd 11.5% a year.
Debt to equity: Aurobindo Pharma Ltd 0.21 vs Cipla Ltd 0.02.
Differences in the numbers, not a recommendation of either stock.
Side by side
| AUROPHARMA | CIPLA | |
|---|---|---|
| Price | ₹1,681.4 | ₹1,378.9 |
| Market cap | ₹96,537 cr | ₹1,11,486 cr |
| P/E | 26.3 | 38.5 |
| P/B | — | 3.2 |
| ROE | 9.9% | 11.8% |
| ROCE | 15.1% | 14.5% |
| Debt / equity | 0.21 | 0.02 |
| Operating margin | 15.1% | 12.5% |
| Dividend yield | 0.24% | 0.94% |
| Sales growth, 3 years (yearly) | 10.7% | 7.3% |
| Profit growth, 3 years (yearly) | 22.1% | 11.5% |
| 1-year return | 51.1% | -13.1% |
| Revenue, last 12 months | ₹34,935 cr | ₹28,139 cr |
| Net profit, last 12 months | ₹3,713 cr | ₹2,897 cr |
| Latest quarter | Jun 2026 | Sept 2026 |
| Quarter net profit | ₹1,033 cr | ₹878 cr |
| Quarter profit vs a year earlier | +25.2% | -35.1% |
| Promoter holding | 51.88% | 29.21% |
| Health check | Strong (8.2/10) | Average (5.6/10) |
Common questions
Which has a higher P/E, Aurobindo Pharma Ltd or Cipla Ltd?
Cipla Ltd trades at the higher P/E (38.5 against 26.3). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Cipla Ltd (11.8% against 9.9%).
Which carries more debt?
Aurobindo Pharma Ltd has the higher debt-to-equity ratio (0.21 against 0.02).